You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Belantamab mafodotin

Showing 26 - 50 of 55
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma, Tumors, Tumors, Plasma Cell Trial (Belantamab Mafodotin-Blmf, Daratumumab, Lenalidomide)

Not yet recruiting
  • Multiple Myeloma
  • +7 more
  • Belantamab Mafodotin-Blmf
  • +3 more
  • (no location specified)
Mar 4, 2022

Multiple Myeloma Trial in Charlotte (Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin)

Recruiting
  • Multiple Myeloma
  • Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
  • Charlotte, North Carolina
    Levine Cancer Institute
Nov 17, 2021

Multiple Myeloma Trial in United States (Belantamab Mafodotin, Nirogacestat)

Not yet recruiting
  • Multiple Myeloma
  • Basking Ridge, New Jersey
  • +6 more
Mar 2, 2022

Myeloma Multiple Trial in Houston (Belantamab mafodotin, Lenalidomide)

Not yet recruiting
  • Myeloma Multiple
  • Houston, Texas
    MD Anderson Cancer Center
Oct 29, 2021

MMRR Treated With Belantamab Mafotidine on Monotherapy

Not yet recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • (no location specified)
May 23, 2022

Multiple Myeloma Trial in Greece, Korea, Republic of, United States (Belantamab mafodotin)

Recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • Tucson, Arizona
  • +21 more
Jul 20, 2022

Relapsed Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma, Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma

Recruiting
  • Relapsed Plasmablastic Lymphoma
  • +2 more
  • Belantamab Mafodotin
  • Boston, Massachusetts
  • +2 more
Sep 20, 2021

Multiple Myeloma Trial in Beijing, Jiang Su Province (Belantamab mafodotin)

Completed
  • Multiple Myeloma
  • Belantamab mafodotin
  • Beijing, China
  • +2 more
Feb 8, 2022

Multiple Myeloma, Refractory Trial in Washington, Hackensack, Neptune (Pembrolizumab, Belantamab mafodotin, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma, Refractory
  • Washington, District of Columbia
  • +2 more
Aug 5, 2022

Multiple Myeloma Trial in Worldwide (Belantamab mafodotin, Bortezomib, Lenalidomide)

Recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Yuma, Arizona
  • +34 more
Jul 22, 2022

Multiple Myeloma Trial (Belantamab mafodotin (GSK2857916) anti-BCMA-immunoconjugate)

Approved for marketing
  • Multiple Myeloma
  • Belantamab mafodotin (GSK2857916) anti-BCMA-immunoconjugate
  • (no location specified)
Mar 9, 2021

Multiple Myeloma Trial in Spain (Belantamab mafodotin, Bortezomib, Lenalidomide)

Recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • +4 more
  • Sevilla, Andalucia, Spain
  • +17 more
Dec 3, 2021

Belantamab Mafodotin in Relapsed and/or Refractory Multiple

Recruiting
  • RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
  • Belantamab mafodotin
  • Albacete, Spain
  • +61 more
Aug 2, 2022

Multiple Myeloma Trial in Athens (Belantamab mafodotin)

Recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • Athens, Attica, Greece
    General Hospital of Athens "Alexandra"
Mar 18, 2021

Multiple Myeloma Trial in Aichi, Okayama, Tokyo (Belantamab mafodotin, Bortezomib, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Aichi, Japan
  • +3 more
Feb 8, 2022

Multiple Myeloma Trial in Worldwide (Belantamab mafodotin)

Recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • New Port Richey, Florida
  • +94 more
Nov 30, 2022

Relapsed/ Refractory Multiple Myeloma Trial in Worldwide (Talquetamab, Belantamab Mafodotin)

Not yet recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • Fayetteville, Arkansas
  • +75 more
Aug 11, 2022

Multiple Myeloma Trial in Worldwide (Belantamab mafodotin, Lenalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Birmingham, Alabama
  • +25 more
Dec 9, 2022

Multiple Myeloma Trial in Worldwide (Belantamab mafodotin frozen liquid, Belantamab mafodotin lyophilized powder)

Active, not recruiting
Has Results
  • Multiple Myeloma
  • Belantamab mafodotin frozen liquid
  • Belantamab mafodotin lyophilized powder
  • New Haven, Connecticut
  • +58 more
Jul 27, 2022

Multiple Myeloma Trial in Worldwide (Belantamab mafodotin, Daratumumab, Bortezomib)

Active, not recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Yuma, Arizona
  • +150 more
Dec 9, 2022

Multiple Myeloma Trial in Worldwide (Belantamab mafodotin, Pomalidomide, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Tucson, Arizona
  • +131 more
Jul 1, 2022

Plasma Cell Myeloma Refractory Trial in Worldwide (Isatuximab SAR650984, Dexamethasone, Pomalidomide)

Recruiting
  • Plasma Cell Myeloma Refractory
  • Isatuximab SAR650984
  • +4 more
  • Chicago, Illinois
  • +18 more
Aug 2, 2022

Relapsed Refractory Multiple Myeloma Trial in United States (Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib,

Recruiting
  • Relapsed Refractory Multiple Myeloma
  • Abemaciclib, dexamethasone, ixazomib, pomalidomide
  • +7 more
  • Phoenix, Arizona
  • +16 more
Sep 9, 2021

Multiple Myeloma Trial in Worldwide (Belantamab mafodotin, Pom/dex (Pomalidomide plus low dose Dexamethasone))

Recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • Pom/dex (Pomalidomide plus low dose Dexamethasone)
  • Tucson, Arizona
  • +163 more
Feb 25, 2022

Reporting of Antibody-Drug Conjugate Associated Sepsis-related

Completed
  • Sepsis (SMQ)
  • +2 more
  • Antibody-Drug Conjugate
  • Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
  • Changsha, Hunan, China
    Central South University
Jun 19, 2022